Longer fasting to reduce stomach contents for people on GLP‑1 medications having upper endoscopy
Official title: Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists
Run by Mayo Clinic · NCT07006142 · Data updated 2026-11-12
This project will test whether a longer fasting period before upper endoscopy reduces stomach contents in people taking GLP‑1 receptor agonist medications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT07006142 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults taking GLP‑1 receptor agonists who are scheduled for elective upper endoscopy with the gastroenterology team and can provide their own consent are ideal candidates.
✕Probably not a fit
Patients having urgent procedures, those with known motility disorders (like gastroparesis or achalasia), recent upper GI barium studies, pancreatitis, use of pro‑motility drugs, or procedures that include colonoscopy or enteroscopy are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial applies a modified fasting protocol for patients taking GLP‑1 receptor agonists who are scheduled for elective upper endoscopy. Gastric residual volume will be measured during endoscopy to determine if prolonged fasting lowers the amount of stomach contents. The goal is to identify a fasting approach that reduces aspiration risk and can be agreed on by perioperative care teams. The protocol excludes urgent procedures and patients with conditions that affect gastric emptying.
Why it matters
Potential benefit: If successful, this could lower the risk of aspiration during anesthesia and create clearer fasting guidance for patients on GLP‑1 medications.
How similar studies have gone: There is limited prior trial data—GLP‑1 receptor agonists are known to slow gastric emptying, but few controlled studies have tested changing fasting times, so the approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing elective upper endoscopy with gastroenterology team Exclusion Criteria: * Urgent or emergent procedure * Inclusion of colonoscopy or antegrade small bowel enteroscopy in planned procedure * Upper GI barium study performed in past 24 hours. * Gastroparesis * Achalasia * Pancreatitis * Use of outpatient pro-motility medications * Patient refusal * Inability for patient to provide own consent
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Study coordinator: Krishnan Ramanujan, MD
- Email: ramanujan.krishnan@mayo.edu
- Phone: 507-422-4898
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using PET/CT imaging to diagnose GLP-1 receptor related diseases
This study is testing a special imaging scan to see if it can help doctors better diagnose cancer in adults who may have diseases related to GLP-1 receptors.
-
Carbon footprint of diagnostic versus therapeutic upper GI endoscopy
This project will measure how much carbon is produced by diagnostic endoscopy for dyspepsia compared with therapeutic endoscopy for non-variceal upper GI bleeding.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.